Eligible	B-P
patients	I-P
will	I-P
present	I-P
AF	I-P
lasting	I-P
less	I-P
than	I-P
43	I-P
hours	I-P
,	I-P
will	I-P
be	I-P
in	I-P
stable	I-P
cardio-pulmonary	I-P
condition	I-P
and	I-P
will	I-P
have	I-P
no	I-P
prior	I-P
history	I-P
of	I-P
advanced	I-P
heart	I-P
failure	I-P
or	I-P
significant	I-P
valvular	I-P
disease	I-P
.	I-P


BACKGROUND	O
Cementing	O
technique	O
is	O
a	O
crucial	O
factor	O
in	O
prosthesis	B-P
fixation	I-P
.	I-P


PATIENTS	O
AND	O
METHODS	O
We	O
randomized	O
50	B-P
THAs	I-I
to	I-I
either	I-I
fingerpacking	I-I
or	I-I
sequential	I-I
pressurization	I-I
(	I-I
including	I-I
individual	I-I
pressurization	I-I
of	I-I
each	I-I
anchorage	I-I
hole	I-I
)	I-I
and	I-P
followed	I-P
the	I-P
patients	I-P
with	I-P
RSA	I-I
for	I-P
5	I-P
years	I-P
.	I-P


The	O
influence	O
of	O
adult	B-I
intervention	I-I
on	O
infants	B-OUT
'	I-OUT
level	I-OUT
of	I-OUT
attention	I-OUT
.	I-OUT


Level	O
of	O
intervention	O
was	O
controlled	O
by	O
systematically	B-I
varying	I-I
the	I-I
manner	I-I
and	I-I
frequency	I-I
with	I-I
which	I-I
objects	I-I
were	I-I
presented	I-I
,	I-I
the	I-I
extent	I-I
to	I-I
which	I-I
the	I-I
experimenter	I-I
talked	I-I
to	I-I
the	I-I
infant	I-I
,	I-I
and	I-I
physical	I-I
proximity	I-I
.	I-I


Infant	O
attention	O
was	O
defined	O
as	O
duration	B-OUT
of	I-OUT
time	I-OUT
spent	I-OUT
examining	I-OUT
objects	I-OUT
.	I-OUT


The	O
results	O
show	O
that	O
level	O
of	O
intervention	B-I
interacts	O
with	O
the	O
child	B-OUT
's	I-OUT
spontaneous	I-OUT
tendency	I-OUT
to	I-OUT
focus	I-OUT
attention	I-OUT
on	O
objects	O
.	O


A	O
randomized	O
controlled	O
trial	O
recently	O
demonstrated	O
that	O
continuous	B-I
positive	I-I
airway	I-I
pressure	I-I
(	I-P
CPAP	I-P
)	I-P
effectively	I-P
decreases	I-P
respiratory	I-OUT
rate	I-OUT
in	I-P
children	I-P
presenting	I-P
to	I-P
Ghanaian	I-P
district	I-P
hospitals	I-P
with	I-P
respiratory	I-P
distress	I-P
.	I-P


Twenty-eight	B-P
nurses	I-P
participated	I-P
in	I-P
the	I-P
study	I-P
,	I-P
9	I-P
first-generation	I-P
and	I-P
19	I-P
second-generation	I-P
.	I-P


First-generation	O
trainees	O
scored	O
significantly	O
higher	O
than	O
second-generation	O
trainees	O
on	O
both	O
skills	B-OUT
and	I-OUT
knowledge	I-OUT
assessments	I-OUT
(	O
p	O
=	O
0.003	O
)	O
.	O


Transient	O
or	O
final	O
side	O
branch	O
occlusion	O
occurred	O
less	O
frequently	O
in	O
patients	B-P
receiving	I-P
EES	I-P
compared	I-P
to	I-P
PES	I-P
(	O
2.8	O
%	O
vs.	O
5.2	O
%	O
,	O
p=0.009	O
)	O
,	O
contributing	O
to	O
the	O
numerically	O
lower	O
rates	B-OUT
of	I-OUT
in-hospital	I-OUT
NQMI	I-OUT
with	O
EES	O
arm	O
compared	O
to	O
PES	O
(	O
0.7	O
%	O
vs.	O
2.3	O
%	O
,	O
p=0.05	O
)	O
.	O


We	O
investigated	O
providers	B-P
'	I-P
in-office	I-P
use	I-P
of	I-P
CDC	I-P
gynecologic	I-P
cancer	I-P
materials	I-P
and	I-P
their	I-P
recognition	I-P
of	I-P
the	I-P
symptoms	I-P
highlighted	I-P
in	I-P
the	I-P
materials	I-P
.	I-P


Distributing	O
consumer	O
education	O
materials	O
in	O
health	O
care	O
provider	O
offices	O
remains	O
a	O
priority	O
for	O
the	O
Inside	O
Knowledge	O
campaign	O
,	O
as	O
the	O
setting	O
where	O
women	O
and	B-P
health	I-P
care	I-P
providers	I-P
interact	O
is	O
one	O
of	O
the	O
most	O
crucial	O
venues	O
to	O
promote	O
awareness	O
of	O
gynecologic	O
cancer	O
symptoms	O
.	O


Efficacy	O
of	O
omeprazole	B-I
versus	O
high-dose	B-I
famotidine	I-I
for	O
prevention	O
of	O
exercise-induced	B-OUT
gastritis	I-OUT
in	O
racing	B-P
Alaskan	I-P
sled	I-P
dogs	I-P
.	I-P


BACKGROUND	O
Omeprazole	B-I
and	O
famotidine	B-I
both	O
reduce	O
severity	O
of	O
exercise-induced	B-OUT
gastritis	I-OUT
,	O
but	O
administering	O
famotidine	O
is	O
easier	O
than	O
administering	O
omeprazole	O
during	O
racing	O
competition	O
.	O


ANIMALS	O
Experiment	O
1	O
:	O
Randomized	B-P
placebo-controlled	I-P
study	I-P
,	I-P
36	I-P
sled	I-P
dogs	I-P
(	I-P
3-8	I-P
years	I-P
)	I-P
;	I-P
Experiment	O
2	O
:	O
Randomized	B-P
positive-control	I-P
study	I-P
,	I-P
52	I-P
sled	I-P
dogs	I-P
(	I-P
2-8	I-P
years	I-P
)	I-P
.	I-P


Mucosal	B-OUT
appearance	I-OUT
was	O
blindly	O
scored	O
by	O
previously	O
described	O
scoring	O
system	O
.	O


Experiment	O
2	O
:	O
Equal	O
numbers	O
of	O
dogs	O
randomly	O
assigned	O
to	O
omeprazole	B-I
(	O
20	O
mg	O
q24h	O
)	O
or	O
high-dose	O
famotidine	B-I
(	O
40	O
mg	O
q12h	O
)	O
groups	O
.	O


RESULTS	O
Famotidine	B-I
reduced	O
the	O
prevalence	O
of	O
clinically	B-OUT
relevant	I-OUT
,	I-OUT
exercise-induced	I-OUT
gastric	I-OUT
lesions	I-OUT
compared	O
with	O
no	O
treatment	O
(	O
7/16	O
versus	O
11/16	O
,	O
P	O
=	O
.031	O
)	O
.	O


BACKGROUND	O
Patients	B-P
with	I-P
chronic	I-OUT
heartburn	I-OUT
but	I-P
with	I-P
no	I-P
endoscopic	I-P
evidence	I-P
of	I-P
erosive	I-P
oesophagitis	I-P
require	I-P
gastric	I-P
acid	I-P
suppression	I-P
to	I-P
relieve	I-OUT
symptoms	I-OUT
.	I-OUT


METHODS	O
Two	O
randomized	O
,	O
double-blind	O
,	O
4-week	O
,	O
multi-centre	O
trials	O
with	O
identical	O
methodology	O
compared	O
once-daily	O
esomeprazole	B-I
,	O
40	B-P
mg	I-P
(	I-P
n	I-P
=	I-P
241	I-P
)	I-P
or	I-P
20	I-P
mg	I-P
(	I-P
n	I-P
=	I-P
234	I-P
)	I-P
,	I-P
with	I-P
placebo	I-I
(	I-P
n	I-P
=	I-P
242	I-P
)	I-P
for	O
the	O
rigorous	O
end-point	O
of	O
complete	B-OUT
resolution	I-OUT
of	I-OUT
heartburn	I-OUT
.	I-OUT


Secondary	O
end-points	O
included	O
the	O
percentage	B-OUT
of	I-OUT
heartburn-free	I-OUT
days	I-OUT
and	I-OUT
the	I-OUT
time	I-OUT
to	I-OUT
first	I-OUT
and	I-OUT
sustained	I-OUT
resolution	I-OUT
of	I-OUT
heartburn	I-OUT
.	I-OUT


RESULTS	O
Patients	O
treated	O
with	O
either	O
dose	O
of	O
esomeprazole	B-I
were	O
two	O
to	O
three	O
times	O
more	O
likely	O
to	O
achieve	O
complete	B-OUT
resolution	I-OUT
of	I-OUT
heartburn	I-OUT
than	O
patients	O
treated	O
with	O
placebo	B-I
(	O
P	O
<	O
0.001	O
)	O
.	O


There	O
is	O
growing	O
evidence	O
of	O
an	O
association	O
between	O
physical	O
illness	O
and	O
problem	O
behavior	O
in	O
children	B-P
with	I-P
developmental	I-P
disabilities	I-P
.	I-P


Following	O
intervention	O
,	O
the	O
behavioral	O
plus	O
medical	O
intervention	O
group	O
showed	O
lower	O
levels	O
of	O
problem	B-OUT
behavior	I-OUT
and	O
completed	B-OUT
more	I-OUT
academic	I-OUT
tasks	I-OUT
than	O
did	O
the	O
medical	O
intervention	O
alone	O
group	O
.	O


The	O
results	O
are	O
discussed	O
with	O
respect	O
to	O
the	O
concept	B-OUT
of	I-OUT
illness	I-OUT
and	I-OUT
pain	I-OUT
as	O
a	O
setting	O
event	O
for	O
problem	O
behavior	O
.	O


The	O
need	O
for	O
research	O
to	O
develop	O
algorithms	O
that	O
allow	O
one	O
to	O
select	O
the	O
best	O
combination	O
of	O
medical	B-I
and	I-I
behavioral	I-I
interventions	I-I
for	O
specific	O
illnesses	O
and	O
contexts	O
is	O
noted	O
.	O


An	O
evaluation	O
of	O
chemical	O
arthrodesis	O
of	O
the	O
proximal	B-P
interphalangeal	I-P
joint	I-P
in	I-P
the	I-P
horse	I-P
by	O
using	O
monoiodoacetate	B-I
.	I-I


Eight	B-P
horses	I-P
received	O
3	O
injections	O
(	O
Weeks	O
0	O
,	O
3	O
,	O
6	O
)	O
of	O
MIA	B-I
(	O
2	O
mL	O
;	O
60	O
mg/mL	O
)	O
into	O
the	O
right	O
or	O
left	O
front	O
PIJ	O
.	O


Peri-operatively	O
,	O
the	O
horses	O
received	O
phenylbutazone	B-I
,	I-I
butorphanol	I-I
,	I-I
and	I-I
abaxial	I-I
sesamoidean	I-I
nerve	I-I
blocks	I-I
to	O
relieve	O
pain	O
.	O


Exercise	B-I
consisted	O
of	O
20	O
minutes	O
of	O
trotting	O
on	O
a	O
treadmill	O
(	O
4	O
m/s	O
)	O
,	O
3	O
days	O
per	O
week	O
for	O
13	O
weeks	O
.	O


Histologic	B-OUT
examination	I-OUT
revealed	I-OUT
thinning	I-OUT
of	I-OUT
the	I-OUT
cartilage	I-OUT
,	I-OUT
diffuse	I-OUT
necrosis	I-OUT
of	I-OUT
chondrocytes	I-OUT
,	I-OUT
with	I-OUT
the	I-OUT
calcified	I-OUT
zone	I-OUT
intact	I-OUT
.	I-OUT


Subjectively	B-OUT
,	I-OUT
exercise	I-OUT
did	I-OUT
not	I-OUT
influence	I-OUT
the	I-OUT
degree	I-OUT
of	I-OUT
cartilage	I-OUT
destruction	I-OUT
.	I-OUT


INTRODUCTION	O
Current	O
evidence	O
suggests	O
that	O
Social	B-I
Stories	I-I
can	O
be	O
effective	O
in	O
tackling	O
problem	B-OUT
behaviours	I-OUT
exhibited	O
by	O
children	B-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
.	I-P


Case	O
reports	O
in	O
children	B-P
with	I-P
autism	I-P
have	O
suggested	O
that	O
these	O
stories	O
can	O
lead	O
to	O
a	O
number	O
of	O
benefits	O
including	O
improvements	O
in	O
social	B-OUT
interactions	I-OUT
and	I-OUT
choice	I-OUT
making	I-OUT
in	O
educational	O
settings	O
.	O


The	O
current	O
study	O
investigated	O
perceptual	B-OUT
learning	I-OUT
in	O
two	O
optimal	O
conditions	O
:	O
conversational	B-I
speech	I-I
(	I-I
Experiment	I-I
1	O
)	O
versus	O
clear	B-I
speech	I-I
(	O
Experiment	O
2	O
)	O
,	O
and	O
three	O
adverse	O
conditions	O
:	O
noise	B-I
(	O
Experiment	O
3a	O
)	O
versus	O
two	B-I
cognitive	I-I
loads	I-I
(	O
Experiments	O
4a	O
and	O
4b	O
)	O
.	O


Perceptual	B-OUT
learning	I-OUT
occurred	O
in	O
the	O
two	O
optimal	B-I
conditions	I-I
and	O
in	O
the	O
two	O
cognitive	B-I
load	I-I
conditions	I-I
,	O
but	O
not	O
in	O
the	O
noise	B-I
condition	I-I
.	I-I


Furthermore	O
,	O
perceptual	B-OUT
learning	I-OUT
occurred	O
only	O
in	O
the	O
first	O
of	O
two	O
sessions	O
for	O
each	O
participant	O
,	O
and	O
only	O
for	O
atypical	O
/s/	O
sounds	O
and	O
not	O
for	O
atypical	O
/f/	O
sounds	O
.	O


The	O
experimental	B-P
group	I-P
(	I-P
n	I-P
=	I-P
80	I-P
)	I-P
were	O
instructed	O
to	O
gargle	B-I
6	I-I
times	I-I
daily	I-I
with	I-I
warm	I-I
saline	I-I
and	O
no	B-I
such	I-I
instructions	I-I
were	O
given	O
to	O
the	O
second	B-P
group	I-P
(	I-P
n	I-P
=	I-P
80	I-P
)	I-P
to	O
serve	O
as	O
controls	B-I
.	I-I


There	O
was	O
a	O
statistical	O
significant	O
difference	O
between	O
the	O
study	O
groups	O
with	O
respect	O
to	O
development	O
of	O
alveolar	B-OUT
osteitis	I-OUT
(	O
X2	O
=	O
15.00	O
,	O
df	O
=	O
1	O
,	O
p	O
=	O
0.001	O
)	O
.The	O
risk	B-OUT
of	I-OUT
development	I-OUT
of	I-OUT
alveolar	I-OUT
osteitis	I-OUT
was	O
4	O
times	O
higher	O
in	O
the	O
control	O
group	O
(	O
OR	O
=	O
4.33	O
,	O
P	O
=	O
0.001	O
)	O
.	O


CONCLUSION	O
Warm	B-I
saline	I-I
mouth	I-I
rinse	I-I
instruction	O
is	O
beneficial	O
in	O
the	O
prevention	O
of	O
development	O
of	O
alveolar	B-OUT
osteitis	I-OUT
after	O
dental	O
extractions	O
.	O


Subjects/Study	O
interventions	O
:	O
Forty-one	B-P
(	I-P
41	I-P
)	I-P
patients	I-P
were	I-P
studied	I-P
.	I-P


Patients	O
received	O
single-needle	B-I
acupuncture	I-I
with	O
a	O
0.2	O
x	O
13	O
mm	O
disposable	O
acupuncture	O
needle	O
(	O
Suzhou	O
Medical	O
Appliances	O
,	O
China	O
)	O
,	O
10-mm	O
deep	O
either	O
at	O
Chengjiang	O
(	O
midline	O
between	O
lower	O
lip	O
and	O
chin	O
)	O
or	O
superficially	O
at	O
a	O
sham	O
point	O
(	O
tip	O
of	O
the	O
chin	O
)	O
during	O
TEE	O
or	O
no	B-I
acupuncture	I-I
for	O
alleviating	O
gag	O
reflex	O
.	O


RESULTS	O
The	O
acupuncture	O
group	O
experienced	O
significantly	O
less	B-OUT
gagging	I-OUT
than	O
the	O
sham	O
group	O
(	O
p	O
=	O
0.037	O
)	O
or	O
the	O
nonacupuncture	O
group	O
(	O
p	O
=	O
0.013	O
)	O
.	O


CONCLUSIONS	O
Acupuncture	B-I
of	I-I
CV24	I-I
is	O
an	O
easy	O
to	O
apply	O
and	O
effective	O
method	O
to	O
reduce	O
gag	B-OUT
reflex	I-OUT
during	O
TEE	O
.	O


A	O
rigorous	O
statistical	O
method	O
of	O
scale	O
construction	O
consisting	O
of	O
a	O
modification	O
of	O
the	O
scale	O
discrimination	O
technique	O
was	O
employed	O
,	O
resulting	O
in	O
a	O
45-item	B-I
questionnaire	I-I
representing	O
three	O
orthogonally	O
derived	O
scales	O
.	O


In	O
a	O
second	O
study	O
of	O
predictive	O
validity	O
,	O
40	B-P
individuals	I-P
were	I-P
randomly	I-P
assigned	I-P
to	O
one	O
of	O
four	O
conditions	O
:	O
relaxation	B-I
training	I-I
,	I-I
tension	I-I
inducement	I-I
,	I-I
pre-postcontrol	I-I
,	I-I
or	I-I
postcontrol	I-I
.	I-I


Randomized	O
trial	O
of	O
a	O
secondhand	B-I
smoke	I-I
exposure	I-I
reduction	I-I
intervention	I-I
among	O
hospital-based	B-P
pregnant	I-P
women	I-P
.	I-P


OBJECTIVE	O
This	O
study	O
sought	O
to	O
assess	O
the	O
effectiveness	B-OUT
of	O
a	O
secondhand	B-I
tobacco	I-I
smoke	I-I
(	I-I
SHS	I-I
)	I-I
prevention	I-I
program	I-I
based	O
on	O
an	O
expanded	O
Health	B-OUT
Belief	I-OUT
Model	I-OUT
(	O
HBM	O
)	O
incorporating	O
self-efficacy	O
among	O
pregnant	B-P
women	I-P
in	I-P
a	I-P
hospital	I-P
setting	I-P
in	I-P
Taiwan	I-P
.	I-P


Participants	B-I
in	I-I
the	I-I
intervention	I-I
group	I-I
(	I-I
n=50	I-I
)	I-I
enrolled	I-I
in	I-I
a	I-I
SHS	I-I
prevention	I-I
program	I-I
based	I-I
on	I-I
the	I-I
HBM	I-I
,	I-I
while	I-I
participants	I-I
in	I-I
the	I-I
comparison	I-I
group	I-I
(	I-I
n=50	I-I
)	I-I
received	I-I
standard	I-I
government-mandated	I-I
counseling	I-I
care	I-I
.	I-I


CONCLUSIONS	O
These	O
results	O
should	O
encourage	O
health	O
professionals	O
to	O
educate	O
pregnant	B-P
women	I-P
regarding	O
the	O
harms	O
of	O
SHS	O
while	O
both	O
empowering	O
and	O
equipping	O
them	O
with	O
the	O
tools	O
to	O
confront	O
their	O
family	O
members	O
and	O
effectively	O
reduce	O
their	O
SHS	B-OUT
exposure	I-OUT
while	O
promoting	O
smoke-free	O
social	O
norms	O
.	O


INTERPRETATION	O
AND	O
CONCLUSIONS	O
Both	O
schemes	O
of	O
chemotherapy	O
followed	O
by	O
radiotherapy	O
produce	O
high	O
percentages	O
of	O
CR	B-OUT
,	I-OUT
low	I-OUT
risk	I-OUT
of	I-OUT
relapse	I-OUT
and	I-OUT
an	I-OUT
acceptable	I-OUT
toxicity	I-OUT
.	I-OUT


The	O
benefits	O
of	O
including	O
clinical	O
factors	O
in	O
rectal	O
normal	O
tissue	O
complication	B-I
probability	I-I
modeling	I-I
after	I-P
radiotherapy	I-P
for	I-P
prostate	I-P
cancer	I-P
.	I-P


Two	B-I
traditional	I-I
dose-based	I-I
models	I-I
(	I-I
Lyman-Kutcher-Burman	I-I
(	I-I
LKB	I-I
)	I-I
and	I-I
Relative	I-I
Seriality	I-I
(	I-I
RS	I-I
)	I-I
and	I-I
a	I-I
logistic	I-I
model	I-I
were	O
fitted	O
using	O
a	O
maximum	O
likelihood	O
approach	O
.	O


The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
a	O
shortened	O
postpartum	O
course	O
of	O
magnesium	B-I
sulphate	I-I
is	O
as	O
effective	O
as	O
the	O
standard	O
Pritchard	O
regimen	O
in	O
controlling	O
fits	O
in	O
eclampsia	O
Between	B-P
January	I-P
and	I-P
June	I-P
2011	I-P
,	I-P
98	I-P
eclamptic	I-P
mothers	I-P
presenting	I-P
at	I-P
the	I-P
labour	I-P
ward	I-P
of	I-P
the	I-P
University	I-P
of	I-P
Maiduguri	I-P
Teaching	I-P
Hospital	I-P
were	O
randomised	O
to	O
receive	O
either	O
the	O
standard	B-I
Pritchard	I-I
regimen	I-I
of	I-I
magnesium	I-I
sulphate	I-I
or	O
a	O
shortened	B-I
postpartum	I-I
course	I-I
in	O
which	O
only	O
two	O
doses	O
of	O
intramuscular	B-I
magnesium	I-I
sulphate	I-I
is	O
given	O
four	O
hours	O
apart	O
.	O


The	O
shortened	O
postpartum	O
course	O
of	O
magnesium	B-I
sulphate	I-OUT
is	O
as	O
effective	B-OUT
as	O
the	O
standard	O
Pritchard	O
regimen	O
in	O
the	O
management	B-OUT
of	I-OUT
eclampsia	I-OUT
.	I-OUT


PoC	O
tests	O
measured	O
(	O
and	O
devices	O
used	O
)	O
in	O
the	O
trial	O
were	O
haemoglobin	B-OUT
A1c	I-OUT
and	I-OUT
urine	I-OUT
albumin	I-OUT
:	I-OUT
creatinine	I-OUT
ratio	I-OUT
(	I-OUT
DCA	I-OUT
2000	I-OUT
)	I-OUT
,	I-OUT
lipids	I-OUT
(	I-OUT
Cholestech	I-OUT
LDX	I-OUT
)	I-OUT
and	I-OUT
international	I-OUT
normalized	I-OUT
ratio	I-OUT
(	I-OUT
CoaguChek	I-OUT
S	I-OUT
)	I-OUT
.	I-OUT


PoCT	B-P
device	I-P
operators	I-P
were	O
provided	O
with	O
a	O
colour-coded	B-I
QC	I-I
Result	I-I
Sheet	I-I
and	I-I
QC	I-I
Action	I-I
Sheet	I-I
for	I-I
on-site	I-I
recording	I-I
and	I-I
interpreting	I-I
of	I-I
their	I-I
results	I-I
.	I-I


Median	B-OUT
within-practice	I-OUT
imprecision	I-OUT
met	O
the	O
analytical	O
goals	O
for	O
all	O
PoC	O
tests	O
,	O
except	O
for	O
high-density	B-OUT
lipoprotein-cholesterol	I-OUT
(	I-OUT
HDL-C	I-OUT
)	I-OUT
where	O
observed	O
performance	O
was	O
outside	O
the	O
minimum	O
goal	O
for	O
one	O
level	O
and	O
one	O
lot	O
number	O
of	O
QC	O
.	O


Most	O
practices	O
achieved	O
the	O
imprecision	B-OUT
goals	O
for	O
all	O
analytes	O
,	O
with	O
the	O
principal	O
exception	O
of	O
HDL-C	B-OUT
.	I-OUT


We	O
conducted	O
this	O
study	O
to	O
evaluate	O
the	O
safety	B-OUT
and	I-OUT
acceptability	I-OUT
of	O
6	O
%	O
cellulose	B-I
sulfate	I-I
(	I-I
CS	I-I
)	I-I
gel	O
as	O
a	O
vaginal	O
microbicide	O
in	B-P
sexually	I-P
abstinent	I-P
and	I-P
active	I-P
HIV-infected	I-P
women	I-P
.	I-P


METHODS	O
Fifty-nine	B-P
HIV-infected	I-P
women	I-P
were	O
enrolled	O
in	O
a	O
randomized	O
double-blind	O
placebo-controlled	B-I
study	O
comparing	O
6	O
%	O
CS	B-I
to	I-I
placebo	I-I
gel	I-I
used	O
for	O
14	O
days	O
.	O


Sexually	B-P
abstinent	I-P
women	I-P
applied	O
gel	O
once	O
or	O
twice	O
daily	O
and	O
sexually	O
active	O
women	O
used	O
gel	O
once	O
daily	O
.	O


RESULTS	O
CS	O
gel	O
was	O
safe	O
with	O
no	O
reported	O
severe	B-OUT
or	I-OUT
life-threatening	I-OUT
adverse	I-OUT
events	I-OUT
(	I-OUT
AE	I-OUT
)	I-OUT
.	I-OUT


Fewer	O
women	O
(	O
62	O
%	O
)	O
who	O
used	O
CS	O
experienced	O
urogenital	B-OUT
AE	I-OUT
than	O
those	O
assigned	O
to	O
placebo	B-I
gel	O
(	O
70	O
%	O
)	O
(	O
P	O
=	O
0.59	O
)	O
.	O


Eleven	O
(	O
19	O
%	O
)	O
women	O
experienced	O
intermenstrual	B-OUT
bleeding	I-OUT
judged	O
to	O
be	O
probably	O
or	O
possibly	O
related	O
to	O
gel	O
use	O
(	O
four	O
in	O
the	O
CS	O
and	O
seven	O
in	O
the	O
placebo	O
gel	O
group	O
)	O
.	O


CONCLUSIONS	O
This	O
Phase	O
I	O
study	O
demonstrated	O
that	O
CS	B-I
vaginal	I-I
gel	I-I
was	O
safe	B-OUT
,	I-OUT
well	I-OUT
tolerated	I-OUT
and	I-OUT
acceptable	I-OUT
by	O
HIV-infected	B-P
women	I-P
and	I-P
their	I-P
male	I-P
partners	I-P
.	I-P


Detection	O
of	O
traumatic	O
arthrotomy	O
of	O
the	O
knee	O
using	O
the	O
saline	B-I
solution	I-I
load	I-I
test	I-I
.	I-I


BACKGROUND	O
The	O
saline	B-I
solution	I-I
load	I-I
test	I-I
helps	O
to	O
determine	O
if	O
a	O
wound	O
extends	O
into	O
the	O
knee	O
joint	O
.	O


METHODS	O
Fifty-six	B-P
consecutive	I-P
patients	I-P
scheduled	I-P
for	I-P
knee	I-P
arthroscopy	I-P
were	O
enrolled	O
.	O


RESULTS	O
The	O
study	O
group	O
included	O
thirty-one	B-P
female	I-P
patients	I-P
and	I-P
twenty-five	I-P
male	I-P
patients	I-P
with	I-P
a	I-P
combined	I-P
average	I-P
age	I-P
of	I-P
fifty	I-P
years	I-P
and	I-P
an	I-P
average	I-OUT
body	I-OUT
mass	I-OUT
index	I-OUT
of	I-P
30.9	I-P
.	I-P


The	O
mean	B-OUT
volumes	I-OUT
of	I-OUT
injected	I-OUT
fluid	I-OUT
needed	I-OUT
for	I-OUT
a	I-OUT
positive	I-OUT
result	I-OUT
at	I-OUT
the	I-OUT
inferomedial	I-OUT
and	I-OUT
superomedial	I-OUT
needle	I-OUT
locations	I-OUT
were	O
64.0	O
and	O
95.2	O
mL	O
,	O
respectively	O
;	O
this	O
difference	O
was	O
significant	O
(	O
p	O
=	O
0.01	O
)	O
.	O


There	O
was	O
no	B-OUT
correlation	I-OUT
between	I-OUT
necessary	I-OUT
injection	I-OUT
volume	I-OUT
and	I-OUT
sex	I-OUT
,	I-OUT
body	I-OUT
mass	I-OUT
index	I-OUT
,	I-OUT
or	I-OUT
knee	I-OUT
circumference	I-OUT
.	I-OUT


Sustained	O
effect	O
of	O
SQ-standardized	O
grass	O
allergy	O
immunotherapy	B-I
tablet	I-I
on	O
rhinoconjunctivitis	O
quality	O
of	O
life	O
.	O


AIM	O
To	O
investigate	O
the	O
sustained	O
effect	O
on	O
quality	O
of	O
life	O
during	O
the	O
grass	O
pollen	O
season	O
1	O
year	O
after	O
3	O
years	O
of	O
treatment	O
with	O
the	O
SQ-standardized	O
grass	B-I
allergy	I-I
immunotherapy	I-I
tablet	I-I
(	I-I
AIT	I-I
)	I-I
,	O
Graza	O
(	O
Phleum	O
pratense	O
75,000	O
SQ-T/2800	O
BAU	O
;	O
ALK	O
,	O
Denmark	O
)	O
.	O


Quality	B-OUT
of	I-OUT
life	I-OUT
assessments	O
were	O
based	O
on	O
the	O
standardized	B-OUT
rhinoconjunctivitis	I-OUT
quality	I-OUT
of	I-OUT
life	I-OUT
questionnaire	I-OUT
(	I-OUT
RQLQ	I-OUT
(	I-OUT
S	I-OUT
)	I-OUT
)	I-OUT
;	I-OUT
completed	O
weekly	O
during	O
the	O
entire	O
grass	O
pollen	O
season	O
.	O


RESULTS	O
During	O
follow-up	O
,	O
the	O
overall	O
RQLQ	B-OUT
(	I-OUT
S	I-OUT
)	I-OUT
score	I-OUT
for	O
the	O
entire	O
grass	O
pollen	O
season	O
was	O
significantly	O
improved	O
in	O
the	O
active	O
group	O
(	O
relative	O
difference	O
to	O
placebo	B-I
:	I-I
23	O
%	O
,	O
P	O
=	O
0.004	O
)	O
.	O


Improvements	O
were	O
found	O
in	O
all	O
seven	O
RQLQ	B-OUT
(	I-OUT
S	I-OUT
)	I-OUT
domains	I-OUT
.	I-OUT


CONCLUSION	O
In	O
subjects	O
inadequately	O
controlled	O
by	O
symptomatic	O
medications	O
,	O
grass	O
AIT	B-I
provided	O
sustained	O
and	O
clinically	O
relevant	O
improvements	O
in	O
rhinoconjunctivitis	B-OUT
quality	I-OUT
of	I-OUT
life	I-OUT
compared	O
to	O
placebo	B-I
.	I-I


HORIZON	O
is	O
a	O
trauma	B-I
focused	I-I
cognitive	I-I
behavioral	I-I
therapy	I-I
based	O
group	O
program	O
with	O
the	O
added	O
component	O
of	O
a	O
preparatory	B-I
parenting	I-I
program	I-I
aimed	O
at	O
improving	O
parental	O
availability	O
;	O
and	O
the	O
added	O
component	O
of	O
parent-child	O
sessions	O
to	O
improve	O
parent-child	O
interaction	O
.	O


Primary	O
outcome	O
measures	O
are	B-OUT
posttraumatic	I-OUT
stress	I-OUT
symptoms	I-OUT
,	I-OUT
and	I-OUT
internalizing	I-OUT
and	I-OUT
externalizing	I-OUT
problems	I-OUT
in	I-OUT
children	I-OUT
.	O


The	O
secondary	O
aim	O
of	O
the	O
study	O
is	O
to	O
test	O
the	O
effect	O
of	O
the	O
two	O
added	O
components	B-OUT
on	I-OUT
adjustment	I-OUT
problems	I-OUT
in	I-OUT
children	I-OUT
and	O
to	O
test	O
whether	O
enhanced	O
effects	O
can	O
be	O
explained	B-OUT
by	I-OUT
changes	I-OUT
in	I-OUT
children	I-OUT
's	I-OUT
responses	I-OUT
towards	O
experienced	O
violence	O
,	O
in	B-OUT
parental	I-OUT
availability	I-OUT
,	I-OUT
and	I-OUT
in	I-OUT
quality	I-OUT
of	I-OUT
parent-child	I-OUT
interaction	I-OUT
.	O


DISCUSSION	O
The	O
current	O
study	O
will	O
enhance	O
our	O
understanding	O
of	O
the	O
efficacy	B-I
interparental	I-I
violence-related	I-I
parental	I-I
components	I-I
added	I-I
to	I-I
trauma	I-I
focused	I-I
cognitive	I-I
behavioral	I-I
group	I-I
program	I-I
for	O
children	O
who	O
have	O
been	O
exposed	O
to	O
IPV	O
.	O


METHODS	O
A	B-P
consecutive	I-P
cohort	I-P
of	I-P
patients	I-P
(	I-P
n	I-P
=	I-P
200	I-P
,	I-P
68	I-P
men	I-P
)	I-P
referred	I-P
to	I-P
acute	I-I
surgical	I-I
correction	I-I
of	I-I
hip	I-I
fracture	I-I
was	I-P
studied	I-P
.	I-P


Troponin	B-I
T	I-I
(	I-I
TnT	I-I
)	I-I
measurements	I-I
and	O
electrocardiographic	B-I
(	I-I
ECG	I-I
)	I-I
recordings	I-I
were	O
performed	O
at	O
admission	O
,	O
before	O
operation	O
,	O
and	O
on	O
the	O
first	O
and	O
2nd	O
postoperative	O
days	O
,	O
which	O
were	O
used	O
for	O
diagnosis	O
.	O


A	O
significant	O
rise	B-OUT
in	I-OUT
TnT	I-OUT
as	O
a	O
sign	O
of	O
myocardial	B-OUT
infarction	I-OUT
was	O
observed	O
in	O
71	O
patients	O
(	O
35.5	O
%	O
)	O
,	O
and	O
25	O
of	O
them	O
had	O
a	O
TnT	B-OUT
elevation	I-OUT
exceeding	O
five	O
times	O
the	O
upper	O
normal	O
limit	O
.	O


Evidence-based	B-OUT
medications	I-OUT
of	O
myocardial	O
infarction	O
were	O
seldom	O
started	O
and	O
cardiologist	O
was	O
consulted	O
in	O
12	O
patients	O
(	O
16.9	O
%	O
)	O
.	O


How	O
to	O
establish	O
equivalence	O
when	O
data	O
are	O
censored	O
:	O
a	O
randomized	B-P
trial	I-P
of	I-P
treatments	I-P
for	I-P
B	I-P
non-Hodgkin	I-P
lymphoma	I-P
.	I-P


The	O
usual	O
logrank	B-I
test	I-I
has	O
to	O
be	O
modified	O
to	O
test	O
whether	O
the	O
true	O
value	O
r	O
of	O
the	O
ratio	O
of	O
hazard	O
rates	O
in	O
two	O
treatment	O
groups	O
is	O
at	O
least	O
equal	O
to	O
a	O
limit	O
value	O
r0	O
.	O


Ambulatory	B-OUT
BP	I-OUT
was	O
performed	O
in	O
the	O
final	O
week	O
of	O
each	O
phase	O
.	O


RESULTS	O
Compared	O
with	O
the	O
placebo	O
phase	O
,	O
end	O
of	O
phase	O
clinic	B-OUT
BP	I-OUT
was	O
unchanged	O
by	O
any	O
of	O
the	O
progestogen	O
treatments	O
.	O


CONCLUSION	O
In	O
a	O
regimen	O
of	O
postmenopausal	O
hormone	O
replacement	O
therapy	O
with	O
a	O
fixed	O
mid-range	O
daily	O
dose	O
of	O
CEE	B-I
combined	O
with	O
a	O
cyclical	O
regimen	O
of	O
a	O
C21	O
progestogen	O
spanning	O
the	O
current	O
clinical	O
dose	O
range	O
,	O
the	O
progestogen	B-I
has	O
either	O
no	O
effect	O
or	O
a	O
small	O
dose-dependent	O
reduction	O
in	O
clinic	B-OUT
and	I-OUT
ambulatory	I-OUT
BPs	I-OUT
over	O
one	O
treatment	O
cycle	O
.	O


The	O
authors	O
assessed	O
the	O
safety	B-OUT
and	O
effectiveness	B-OUT
of	O
atomoxetine	B-I
monotherapy	O
compared	O
with	O
combined	O
atomoxetine/fluoxetine	B-I
therapy	I-I
in	O
a	O
population	B-P
of	I-P
children	I-P
and	I-P
adolescents	I-P
with	I-P
ADHD	I-P
and	I-P
concurrent	I-P
symptoms	I-P
of	I-P
depression	I-P
or	I-P
anxiety	I-P
.	I-P


Some	O
differences	B-OUT
between	O
treatment	O
groups	O
for	O
depressive	B-OUT
symptoms	I-OUT
were	O
significant	B-OUT
,	O
but	O
the	O
magnitudes	B-OUT
of	O
the	O
differences	O
were	O
small	B-OUT
and	O
likely	O
of	O
limited	O
clinical	O
importance	O
.	O


The	O
combination	O
group	O
had	O
greater	B-OUT
increases	I-OUT
in	I-OUT
blood	I-OUT
pressure	I-OUT
and	I-OUT
pulse	I-OUT
than	O
did	O
the	O
monotherapy	O
group	O
.	O


Anxiety	B-OUT
and	I-OUT
depressive	I-OUT
symptoms	I-OUT
also	O
improved	O
,	O
but	O
the	O
absence	O
of	O
a	O
placebo-only	O
arm	O
does	O
not	O
allow	O
us	O
to	O
conclude	O
that	O
these	O
effects	O
are	O
specifically	O
the	O
result	O
of	O
treatment	O
with	O
atomoxetine	B-I
.	I-I


Combined	B-I
atomoxetine/fluoxetine	I-I
therapy	O
was	O
well	O
tolerated	O
.	O


Double-blind	O
comparison	O
of	O
the	O
efficacy	B-OUT
and	I-OUT
safety	I-OUT
of	O
trandolapril	B-I
2	O
mg	O
and	O
hydrochlorothiazide	B-I
25	O
mg	O
in	O
patients	B-P
with	I-P
mild-to-moderate	I-P
essential	I-P
hypertension	I-P
.	I-P


This	O
multicenter	O
international	O
trial	O
recruited	O
205	B-P
patients	I-P
from	I-P
16	I-P
investigators	I-P
.	I-P


After	O
a	O
4-week	O
,	O
single-blind	B-I
placebo	I-I
run-in	O
,	O
patients	O
were	O
randomized	O
to	O
receive	O
16	O
weeks	O
of	O
trandolapril	B-I
2	O
mg/day	O
(	O
68	O
patients	O
)	O
,	O
hydrochlorothiazide	B-I
(	I-I
HCTZ	I-I
)	I-I
25	O
mg/day	O
(	O
68	O
patients	O
)	O
,	O
or	B-I
the	I-I
combination	I-I
(	O
69	O
patients	O
)	O
.	O


Blood	B-OUT
pressure	I-OUT
was	O
normalized	O
in	O
the	O
combination	O
group	O
in	O
67	O
%	O
of	O
patients	O
,	O
a	O
significantly	O
higher	O
proportion	O
than	O
either	O
trandolapril	O
(	O
63	O
%	O
)	O
or	O
HCTZ	O
(	O
60	O
%	O
;	O
p	O
=	O
0.04	O
)	O
.	O


The	O
incidence	O
of	O
adverse	B-OUT
events	I-OUT
was	O
similar	O
in	O
all	O
three	O
groups	O
.	O


Furthermore	O
,	O
the	O
combination	O
of	O
the	O
two	O
drugs	O
was	O
shown	O
to	O
enhance	O
the	O
antihypertensive	B-OUT
effect	I-OUT
of	O
the	O
two	O
compounds	O
alone	O
.	O


PURPOSE	O
To	O
evaluate	O
the	O
effects	O
of	O
diltiazem	B-I
and	I-I
propranolol	I-I
in	O
patients	B-P
with	I-P
unstable	I-P
angina	I-P
.	I-P


METHODS	O
Fifty-six	B-P
patients	I-P
with	I-P
unstable	I-P
angina	I-P
,	I-P
mean	I-P
age	I-P
of	I-P
55.4	I-P
+/-	I-P
8.5	I-P
,	I-P
41	I-P
men	I-P
and	I-P
15	I-P
women	I-P
,	O
were	O
evaluated	O
in	O
a	O
randomized	O
,	O
double-blind	O
study	O
of	O
two	O
groups	O
of	O
patients	O
treated	O
with	O
diltiazem	B-I
or	I-I
propranolol	I-I
at	O
total	O
daily	O
doses	O
of	O
180	O
mg	O
and	O
120	O
mg	O
respectively	O
during	O
the	O
first	O
48	O
hours	O
.	O


The	O
first	O
48	O
hours	O
,	O
four	O
times	O
daily	O
,	O
clinical	B-OUT
evaluation	I-OUT
,	I-OUT
CKMB	I-OUT
data	I-OUT
,	I-OUT
ECG	I-OUT
were	O
obtained	O
and	O
two	O
times	O
daily	O
until	O
7th	O
day	O
.	O


The	O
SAP	B-OUT
,	I-OUT
DAP	I-OUT
,	I-OUT
HR	I-OUT
and	I-OUT
RR	I-OUT
did	O
not	O
show	O
statistical	O
differences	O
between	O
groups	O
.	O


Moisture-vapour-permeable	B-I
film	I-I
as	O
an	O
outpatient	B-P
burn	I-P
dressing	I-P
.	I-P


The	O
MVPF	B-I
group	O
demonstrated	O
a	O
39.0	O
per	O
cent	O
greater	O
reduction	O
in	O
pain	B-OUT
after	O
application	O
of	O
the	O
dressing	O
over	O
the	O
silver	B-I
sulphadiazine	I-I
group	O
.	O


The	O
effects	O
of	O
haloperidol	B-I
on	O
behavioral	B-OUT
symptoms	I-OUT
and	I-OUT
learning	I-OUT
were	O
critically	O
assessed	O
in	O
autistic	B-P
children	I-P
in	O
an	O
ongoing	O
double-blind	O
placebo-controlled	B-I
clinical	O
trial	O
.	O


A	O
clear	O
difference	O
in	O
morphine	B-OUT
requirement	I-OUT
became	O
evident	O
after	O
24	O
hours	O
(	O
P	O
=	O
0.010	O
)	O
.	O


Hospital	B-OUT
stay	I-OUT
was	O
significantly	O
shorter	O
in	O
the	O
SH	B-I
group	O
(	O
SH	O
2.2	O
+/-	O
1.2	O
[	O
0	O
;	O
5.0	O
]	O
versus	O
MM	B-I
3.1	O
+/-	O
1.7	O
[	O
1	O
;	O
8.0	O
]	O
P	O
<	O
0.001	O
)	O
.	O


At	O
1	O
year	O
,	O
no	O
differences	B-OUT
in	O
the	O
resolution	B-OUT
of	I-OUT
symptoms	I-OUT
were	O
observed	O
between	O
the	O
2	O
groups	O
,	O
and	O
over	O
2	O
years	O
,	O
the	O
overall	B-OUT
incidence	I-OUT
of	I-OUT
complications	I-OUT
was	O
the	O
same	O
,	O
specifically	O
fecaloma	B-OUT
(	O
P	O
=	O
0.003	O
)	O
in	O
the	O
MM	B-I
group	O
and	O
external	B-OUT
hemorrhoidal	I-OUT
thrombosis	I-OUT
(	O
P	O
=	O
0.006	O
)	O
in	O
the	O
SH	B-I
group	O
.	O


The	O
technique	O
is	O
reproducible	O
and	O
can	O
achieve	O
comparable	O
outcomes	B-OUT
as	O
those	O
of	O
the	O
MM	B-I
technique	O
as	O
long	O
as	O
the	O
well-described	O
steps	O
of	O
the	O
technique	O
are	O
followed	O
.	O


Its	O
effectiveness	B-OUT
in	O
relieving	O
symptoms	O
is	O
equivalent	O
to	O
conventional	O
surgery	O
,	O
and	O
the	O
number	B-OUT
of	I-OUT
hemorrhoidal	I-OUT
prolapse	I-OUT
recurrences	I-OUT
at	I-OUT
2	I-OUT
years	I-OUT
is	O
not	O
significantly	O
different	O
.	O


A	O
double-blind	O
randomised	O
trial	O
compared	O
20	B-P
patients	I-P
with	I-P
leukaemia	I-P
receiving	I-P
human	I-I
recombinant	I-I
granulocyte	I-I
macrophage	I-I
colony	I-I
stimulating	I-I
factor	I-I
(	I-I
GM	I-I
CSF	I-I
)	I-I
,	I-P
with	I-P
20	I-P
patients	I-P
receiving	I-P
placebo	I-I
for	I-I
14	I-I
days	I-I
after	I-I
allogeneic	I-I
matched	I-I
sibling	I-I
bone	I-I
marrow	I-I
transplantation	I-I
.	I-I


The	O
median	B-OUT
neutrophil	I-OUT
count	I-OUT
at	O
14	O
days	O
was	O
significantly	O
higher	O
in	O
the	O
GM	B-I
CSF	I-I
group	O
(	O
1.90	O
vs.	O
0.46	O
x	O
10	O
(	O
9	O
)	O
/l	O
)	O
.	O


The	O
duration	B-OUT
of	I-OUT
hospital	I-OUT
stay	I-OUT
,	I-OUT
the	I-OUT
number	I-OUT
of	I-OUT
antibiotic	I-OUT
days	I-OUT
,	I-OUT
and	I-OUT
the	I-OUT
number	I-OUT
of	I-OUT
fever	I-OUT
days	I-OUT
was	O
the	O
same	O
for	O
both	B-P
patient	I-P
groups	I-P
.	I-P


The	O
GM-CSF	B-I
group	O
had	O
lower	O
haemoglobin	B-OUT
concentrations	I-OUT
and	I-OUT
platelets	I-OUT
counts	I-OUT
,	I-OUT
and	I-OUT
higher	I-OUT
plasma	I-OUT
urea	I-OUT
creatinine	I-OUT
and	I-OUT
bilirubin	I-OUT
,	O
than	O
the	O
placebo	O
group	O
.	O


Tumor	B-OUT
budding	I-OUT
is	O
an	O
independent	O
predictor	O
of	O
outcome	O
in	O
AJCC/UICC	B-P
stage	I-P
II	I-P
colorectal	I-P
cancer	I-P
.	I-P


RESULTS	O
The	O
infiltrating	O
growth	O
pattern	O
was	O
significantly	O
associated	O
with	O
histological	O
subtype	O
and	O
lymphovascular	O
invasion	O
,	O
while	O
high-grade	O
budding	O
was	O
significantly	O
associated	O
with	O
tumor	B-OUT
grade	I-OUT
and	I-OUT
lymphovascular	I-OUT
invasion	I-OUT
.	I-OUT


Cox	O
's	O
proportional	O
hazards	O
regression	O
models	O
proved	O
tumor	B-I
budding	I-I
to	O
be	O
an	O
independent	O
predictor	O
of	O
disease	B-OUT
progression	I-OUT
(	O
hazard	O
ratio	O
3.91	O
,	O
95	O
%	O
confidence	O
interval	O
1.3-11.77	O
;	O
P	O
=	O
0.02	O
)	O
and	B-OUT
cancer-related	I-OUT
death	I-OUT
(	O
hazard	O
ratio	O
5.90	O
,	O
95	O
%	O
confidence	O
interval	O
1.62-21.51	O
;	O
P	O
=	O
0.007	O
)	O
.	O


CONCLUSIONS	O
Tumor	O
budding	O
independently	O
predicted	O
patient	O
outcome	B-P
in	I-P
patients	I-P
with	I-P
AJCC/UICC	I-P
stage	I-P
II	I-P
colorectal	I-P
cancer	I-P
and	O
may	O
therefore	O
be	O
used	O
for	O
accurate	O
prognostication	O
,	O
patient	O
counseling	O
,	O
and	O
design	O
of	O
clinical	O
trials	O
by	O
using	B-I
integrated	I-I
multimodal	I-I
therapy	I-I
.	O


Early	O
versus	O
late	O
hCG	B-I
administration	I-I
to	O
trigger	O
ovulation	O
in	O
mild	O
stimulated	O
IUI	O
cycles	O
:	O
a	O
randomized	O
clinical	O
trial	O
.	O


OBJECTIVES	O
To	O
verify	O
non-inferiority	O
of	O
the	O
clinical	O
pregnancy	O
rate	O
of	O
Early	B-I
hCG	I-I
administration	I-I
(	O
leading	O
follicle	O
sizes	O
within	O
16.0-16.9	O
mm	O
in	O
diameter	O
)	O
compared	O
to	O
Late	B-I
hCG	I-I
administration	I-I
(	O
leading	O
follicle	O
sizes	O
within	O
18.0-18.9	O
mm	O
in	O
diameter	O
)	O
.	O


Six	B-P
hundred	I-P
and	I-P
twelve	I-P
infertile	I-P
women	I-P
candidates	I-P
for	I-P
intrauterine	I-P
insemination	I-P
(	I-P
IUI	I-P
)	I-P
received	O
HP-hMG	B-I
75	O
IU/day	O
SC	O
from	O
cycle	O
days	O
4	O
to	O
8	O
and	O
then	O
as	O
per	O
ovarian	O
response	O
.	O


Managing	O
repetitive	O
behaviours	O
in	O
young	B-P
children	I-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
(	I-P
ASD	I-P
)	I-P
:	I-P
pilot	O
randomised	O
controlled	O
trial	O
of	O
a	O
new	O
parent	B-P
group	O
intervention	O
.	O


We	O
report	O
the	O
acceptability	O
,	O
feasibility	O
and	O
impact	O
on	O
child	O
functioning	O
of	O
a	O
new	O
8	B-I
weeks	I-I
parent-group	I-I
intervention	I-I
to	I-I
manage	I-I
restricted	I-I
and	I-I
repetitive	I-I
behaviours	I-I
(	I-P
RRB	I-P
)	I-P
in	I-P
young	I-P
children	I-P
with	I-P
ASD	I-P
aged	I-P
3-7	I-P
years	I-P
.	I-P


BACKGROUND	O
In	O
1998	O
,	O
mandatory	O
folic	O
acid	O
fortification	O
of	O
white	B-I
flour	I-I
and	I-I
select	I-I
cereal	I-I
grain	I-I
products	I-I
was	O
implemented	O
in	O
Canada	B-P
with	O
the	O
intention	O
to	O
increase	O
dietary	B-I
folate	I-I
intakes	I-I
of	O
reproducing	B-P
women	I-P
.	I-P


In	O
response	O
to	O
improved	O
blood	O
folate	O
concentrations	O
,	O
many	O
health	O
care	O
professionals	O
are	O
asking	O
whether	O
a	O
folic	B-I
acid	I-I
supplement	I-I
is	O
necessary	O
for	O
NTD	O
prevention	O
among	O
women	B-P
with	I-P
high	I-P
blood	I-P
folate	I-P
values	I-P
,	O
and	O
how	O
reliably	O
high	O
RBC	O
folate	O
concentrations	O
predict	O
folate	O
intakes	O
shown	O
in	O
randomized	O
controlled	O
trials	O
to	O
be	O
protective	O
against	O
NTDs	O
.	O


The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
how	O
predictive	O
blood	B-OUT
folate	I-OUT
concentrations	I-OUT
and	I-OUT
folate	I-OUT
intakes	I-OUT
are	O
of	O
each	O
other	O
in	O
a	O
sample	O
of	O
well-educated	B-P
lactating	I-P
Canadian	I-P
women	I-P
exposed	I-P
to	I-P
high	I-P
levels	I-P
of	I-P
synthetic	I-P
folate	I-P
.	I-P


More	O
studies	O
are	O
needed	O
to	O
examine	O
the	O
relationship	O
between	O
blood	B-OUT
folate	I-OUT
concentration	I-OUT
and	O
NTD	O
risk	O
.	O


After	O
initial	O
preparation	O
,	O
the	O
defects	O
were	O
randomly	O
assigned	O
in	O
each	O
patient	O
to	O
either	O
GTR-group	B-I
or	I-P
OFD-group	I-I
.	I-P


The	O
radiographs	B-I
were	O
analyzed	O
by	O
subtraction	O
radiography	O
.	O


RESULTS	O
Comparing	O
baseline	O
to	O
6-month	O
results	O
,	O
both	O
groups	O
showed	O
statistically	O
significant	O
probing	B-OUT
depth	I-OUT
reduction	I-OUT
(	I-OUT
PD	I-OUT
)	I-OUT
,	I-OUT
horizontal	I-OUT
clinical	I-OUT
attachment	I-OUT
level	I-OUT
(	I-OUT
CAL-h	I-OUT
)	I-OUT
gain	I-OUT
,	I-OUT
and	I-OUT
increase	I-OUT
in	I-OUT
gingival	I-OUT
recession	I-OUT
(	I-OUT
GR	I-OUT
)	I-OUT
.	I-OUT


Comparing	O
the	O
two	O
treatments	O
,	O
no	O
statistically	O
significant	O
differences	O
were	O
found	O
in	O
PD	B-OUT
reduction	I-OUT
(	O
GTR	O
:	O
1.67	O
mm	O
;	O
OFD	O
:	O
2.51	O
mm	O
,	O
P	O
=	O
0.26	O
)	O
,	O
CAL-v	B-OUT
gain	I-OUT
(	O
GTR	O
:	O
0.62	O
mm	O
;	O
OFD	O
:	O
1.16	O
mm	O
,	O
P=	O
0.37	O
)	O
,	O
and	O
GR	B-OUT
increase	I-OUT
(	O
GTR	O
:	O
1.04	O
mm	O
;	O
OFD	O
:	O
1.24	O
mm	O
,	O
P	O
=	O
0.31	O
)	O
.	O


GTR	B-I
provided	O
complete	O
closure	B-OUT
of	I-OUT
the	I-OUT
furcation	I-OUT
defect	I-OUT
in	O
two	O
sites	O
and	O
superior	B-OUT
horizontal	I-OUT
clinical	I-OUT
attachment	I-OUT
level	I-OUT
gain	I-OUT
(	O
GTR	O
:	O
2.27	O
mm	O
;	O
OFD	O
:	O
1.01	O
mm	O
,	O
P	O
=	O
0.05	O
)	O
.	O


Utilization	O
of	O
health	B-I
care	I-I
services	I-I
by	O
patients	B-P
with	I-P
chronic	I-P
obstructive	I-P
pulmonary	I-P
disease	I-P
.	I-P


No	O
overall	O
trend	O
for	O
lower	O
RU	B-OUT
was	O
associated	O
with	O
sibenadet	O
therapy	O
,	O
which	O
correlates	O
with	O
the	O
lack	O
of	O
sustained	O
clinical	O
effect	O
seen	O
in	O
studies	O
conducted	O
concurrently	O
.	O


Physicians	O
were	O
seen	O
to	O
be	O
the	O
most	O
common	O
source	O
of	O
care	O
for	O
patients	O
with	O
COPD	O
and	O
more	O
of	O
the	O
patients	B-P
with	I-P
severe	I-P
COPD	I-P
(	I-P
stage	I-P
III	I-P
)	I-P
than	I-P
mild	I-P
(	I-P
stage	I-P
I	I-P
)	I-P
were	O
seen	O
to	O
utilize	O
the	O
most	O
expensive	O
resources	O
(	O
e.g	O
.	O


Beliefs	B-I
underlying	O
the	O
intention	O
to	O
donate	O
again	O
among	O
first-time	B-P
blood	I-P
donors	I-P
who	I-P
experience	I-P
a	I-P
mild	I-P
adverse	I-P
event	I-P
.	I-P


The	O
findings	O
provide	O
insight	O
into	O
those	O
messages	B-I
that	O
could	O
be	O
communicated	O
via	O
the	O
mass	O
media	O
or	O
in	O
targeted	O
communications	O
to	O
retain	O
first-time	B-P
donors	I-P
who	O
have	O
experienced	O
a	O
mild	O
vasovagal	O
reaction	O
.	O


[	O
Initial	O
nuclear	B-I
magnetic	I-I
resonance	I-I
tomography	I-I
results	O
of	O
the	O
treatment	B-P
course	I-P
of	I-P
avascular	I-P
femur	I-P
head	I-P
necrosis	I-P
after	I-P
femoral	I-P
core	I-P
decompression	I-P
]	I-P
.	I-P


Aminocaproic	B-I
acid	I-I
versus	O
prednisone	B-I
for	O
the	O
treatment	O
of	O
traumatic	B-P
hyphema	I-P
.	I-P


We	O
report	O
characteristics	O
of	O
a	O
representative	B-P
sample	I-P
(	I-P
N	I-P
=	I-P
2,324	I-P
)	I-P
of	I-P
beachgoers	I-P
in	I-P
Southeastern	I-P
New	I-P
England	I-P
during	I-P
the	I-P
summer	I-P
of	I-P
1995	I-P
.	I-P


Hyperbaric	B-I
oxygen	I-I
attenuation	O
of	O
lipopolysaccharide-induced	B-P
acute	I-P
lung	I-P
injury	I-P
involves	O
heme	O
oxygenase-1	O
.	O


We	O
sought	O
to	O
investigate	O
the	O
role	O
of	O
heme	O
oxygenase-1	O
(	O
HO-1	O
)	O
on	O
this	O
HBO	O
inhibition	O
of	O
iNOS	O
induction	O
and	O
acute	O
lung	O
injury	O
in	O
septic	O
rat	B-P
lungs	O
.	O


With	O
or	O
without	O
HBO	B-I
pre-treatment	O
,	O
the	O
rats	B-P
were	O
further	O
divided	O
into	O
the	O
following	O
subgroups	O
(	O
n	O
=	O
6	O
)	O
:	O
(	O
i	O
)	O
LPS	B-I
injection	I-I
,	I-I
(	I-I
ii	I-I
)	I-I
normal	I-I
saline	I-I
(	I-I
N/S	I-I
)	I-I
injection	I-I
,	I-I
(	I-I
iii	I-I
)	I-I
hemin	I-I
(	I-I
a	I-I
HO-1	I-I
inducer	I-I
)	I-I
plus	I-I
LPS	I-I
,	I-I
(	I-I
iv	I-I
)	I-I
hemin	I-I
alone	I-I
,	I-I
(	I-I
v	I-I
)	I-I
tin	I-I
protoporphyrin	I-I
(	I-I
SnPP	I-I
;	I-I
a	I-I
HO-1	I-I
inhibitor	I-I
)	I-I
plus	I-I
LPS	I-I
,	I-I
and	I-I
(	I-I
vi	I-I
)	I-I
SnPP	I-I
alone	I-I
.	I-I


Furthermore	O
,	O
this	O
HBO	B-I
attenuation	O
of	O
iNOS	O
expression	O
involves	O
HO-1	O
induction	O
.	O


Occurrence	B-OUT
and	I-OUT
needed	I-OUT
days	I-OUT
for	I-OUT
healing	I-OUT
of	I-OUT
minor	I-OUT
RAS	I-OUT
were	O
recorded	O
during	O
the	O
two	O
phases	O
and	O
compared	O
.	O


RESULTS	O
alpha-Linolenic	B-OUT
acid	I-OUT
concentrations	I-OUT
in	I-OUT
the	I-OUT
plasma	I-OUT
phospholipid	I-OUT
fraction	I-OUT
increased	I-OUT
significantly	O
in	O
both	O
groups	O
during	O
the	O
experimental	O
phase	O
to	O
a	O
similar	O
extent	O
.	O


The	O
effect	O
of	O
cessation	O
of	O
raloxifene	B-I
treatment	O
on	O
bone	B-P
turnover	I-P
in	I-P
postmenopausal	I-P
women	I-P
.	I-P


Our	O
aim	O
was	O
to	O
determine	O
the	O
effect	O
of	O
cessation	O
of	O
raloxifene	B-I
treatment	O
on	O
bone	B-OUT
turnover	I-OUT
and	O
bone	B-OUT
mineral	I-OUT
density	I-OUT
(	I-OUT
BMD	I-OUT
)	I-OUT
in	O
postmenopausal	B-P
,	I-P
osteopenic	I-P
women	I-P
.	I-P


Women	B-P
aged	I-P
50	I-P
to	I-P
80	I-P
years	I-P
received	O
raloxifene	B-I
for	O
96	O
weeks	O
and	O
were	O
then	O
randomized	O
to	O
continue	O
raloxifene	B-I
(	I-P
group	I-P
1	I-P
,	I-P
n=20	I-P
)	I-P
or	I-I
placebo	I-I
(	I-P
group	I-P
2	I-P
,	I-P
n=20	I-P
)	I-P
for	I-P
a	I-P
further	I-P
96	I-P
weeks	I-P
.	I-P


Following	O
cessation	O
of	O
raloxifene	B-I
(	O
group	O
2	O
)	O
,	O
bone	B-OUT
markers	I-OUT
returned	O
to	O
baseline	O
levels	O
(	O
by	O
120	O
weeks	O
)	O
.	O


The	O
beneficial	O
effect	O
on	O
bone	B-OUT
turnover	I-OUT
of	O
96	O
weeks	O
of	O
raloxifene	O
was	O
lost	O
6	O
months	O
after	O
cessation	O
of	O
treatment	O
.	O


Effects	O
of	O
hydraulic	O
circuit	O
training	O
on	O
cardiovascular	B-P
function	I-P
.	I-P


Following	O
training	O
VO2max	B-OUT
(	I-OUT
ml.kg-1	I-OUT
min-1	I-OUT
)	I-OUT
was	O
significantly	O
increased	O
in	O
all	O
training	O
groups	O
(	O
18.0	O
,	O
12.5	O
,	O
and	O
11.3	O
%	O
for	O
cycle	O
,	O
HCTsub	O
,	O
and	O
HCTmax	B-OUT
groups	I-OUT
,	O
respectively	O
;	O
P	O
less	O
than	O
0.05	O
)	O
.	O


The	O
increase	O
in	O
VO2max	B-OUT
observed	O
in	O
the	O
cycle	O
group	O
was	O
significantly	O
greater	O
than	O
that	O
recorded	O
by	O
the	O
two	O
HCT	O
groups	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O


These	O
findings	O
suggest	O
that	O
both	O
maximal	O
and	O
submaximal	O
HCT	O
programs	O
can	O
elicit	O
improvements	O
in	O
cardiovascular	B-OUT
fitness	I-OUT
.	I-OUT


UNLABELLED	O
The	O
purpose	O
of	O
this	O
randomized	O
crossover	O
trial	O
was	O
to	O
determine	O
the	O
effects	O
on	O
autonomic	O
responses	O
in	O
preterm	B-P
infants	I-P
of	I-P
longer	I-P
Kangaroo	I-I
Care	I-I
(	I-P
30	I-P
minutes	I-P
,	I-P
KC30	I-I
)	I-I
and	I-P
shorter	I-P
KC	I-I
(	I-P
15	I-P
minutes	I-P
,	I-P
KC15	I-I
)	I-I
before	I-P
and	I-P
throughout	I-P
heel	I-P
stick	I-P
compared	I-P
with	I-P
incubator	I-I
care	I-I
(	I-I
IC	I-I
)	I-I
.	I-P


HR	B-OUT
changes	O
from	O
Baseline	O
to	O
Heel	O
Stick	O
were	O
significantly	O
less	O
in	O
KC30	O
and	O
KC15	O
than	O
in	O
IC	O
,	O
and	O
more	O
infants	O
had	O
HR	B-OUT
decrease	O
in	O
IC	O
than	O
in	O
2	O
KC	O
conditions	O
.	O


In	O
all	O
3	O
conditions	O
,	O
LF/HF	B-OUT
ratio	I-OUT
decreased	O
from	O
Baseline	O
to	O
Heel	O
Stick	O
and	O
increased	O
to	O
Recovery	O
;	O
no	O
differences	O
were	O
found	O
between	O
IC	B-I
and	O
two	O
KC	B-I
conditions	O
.	O


The	O
findings	O
support	O
that	O
KC	B-I
is	O
a	O
safe	O
and	O
effective	O
pain	O
intervention	O
in	O
the	O
neonatal	O
intensive	O
care	O
unit	O
.	O


Finally	O
,	O
average	B-OUT
VAS	I-OUT
was	O
clearly	O
lower	O
(	O
p	O
<	O
0.01	O
)	O
after	O
coablation	O
as	O
compared	O
to	O
epidural	B-I
injections	I-I
.	O


From	O
our	O
study	O
we	O
believe	O
that	O
acupuncture	B-I
can	O
be	O
used	O
as	O
one	O
of	O
the	O
many	O
treatments	O
for	O
patients	B-P
with	I-P
cancer	I-P
.	I-P


A	O
randomized	O
comparison	O
of	O
the	O
effect	O
of	O
two	O
prelinguistic	B-I
communication	I-I
interventions	I-I
on	O
the	O
acquisition	O
of	O
spoken	O
communication	O
in	O
preschoolers	B-P
with	I-P
ASD	I-P
.	I-P


RESULTS	O
PECS	B-OUT
was	I-OUT
more	I-OUT
successful	I-OUT
than	I-OUT
RPMT	I-OUT
in	I-OUT
increasing	I-OUT
the	I-OUT
number	I-OUT
of	I-OUT
nonimitative	I-OUT
spoken	I-OUT
communication	I-OUT
acts	I-OUT
and	I-OUT
the	I-OUT
number	I-OUT
of	I-OUT
different	I-OUT
nonimitative	I-OUT
words	I-OUT
used	I-OUT
at	I-OUT
the	I-OUT
posttreatment	I-OUT
period	I-OUT
.	I-OUT


Considering	O
growth	O
over	O
all	O
3	O
measurement	O
periods	O
,	O
an	O
exploratory	O
analysis	O
showed	O
that	O
growth	B-OUT
rate	I-OUT
of	I-OUT
the	I-OUT
number	I-OUT
of	I-OUT
different	I-OUT
nonimitative	I-OUT
words	I-OUT
was	I-OUT
faster	I-OUT
in	I-OUT
the	I-OUT
PECS	I-OUT
group	O
than	O
in	O
the	O
RPMT	O
group	O
for	O
children	O
who	O
began	O
treatment	O
with	O
relatively	O
high	O
object	O
exploration	O
.	O


Effect	O
of	O
enamel	B-I
preparation	I-I
method	I-I
on	O
in	O
vitro	O
marginal	B-OUT
microleakage	I-OUT
of	O
a	O
flowable	O
composite	O
used	O
as	O
pit	O
and	O
fissure	O
sealant	O
.	O


METHODS	O
Thirty	B-P
premolars	I-P
were	O
divided	O
into	O
three	O
groups	O
:	O
I	O
-	O
high-speed	B-I
handpiece	I-I
+	I-I
37	I-I
%	I-I
phosphoric	I-I
acid	I-I
;	I-I
II	O
-	O
Er	B-I
:	I-I
YAG	I-I
laser	I-I
(	I-I
350	I-I
mJ	I-I
,	I-I
4	I-I
Hz	I-I
and	I-I
112	I-I
J/cm	I-I
(	I-I
2	I-I
)	I-I
)	I-I
+	I-I
37	I-I
%	I-I
phosphoric	I-I
acid	I-I
;	I-I
and	O
III	O
-	O
Er	B-I
:	I-I
YAG	I-I
laser	I-I
(	I-I
350	I-I
mJ	I-I
,	I-I
4	I-I
Hz	I-I
and	I-I
112	I-I
J/cm	I-I
(	I-I
2	I-I
)	I-I
)	I-I
+	I-I
Er	I-I
:	I-I
YAG	I-I
laser	I-I
(	I-I
80	I-I
mJ	I-I
,	I-I
4	I-I
Hz	I-I
,	I-I
and	I-I
25	I-I
mJ/cm	I-I
(	I-I
2	I-I
)	I-I
)	I-I
.	O


All	O
cavities	B-P
received	O
the	O
same	O
adhesive	O
system	O
and	O
were	O
restored	O
with	O
flowable	O
composite	O
according	O
to	O
manufacturer	O
's	O
instructions	O
.	O


Teeth	O
were	O
submitted	O
to	O
thermal	B-I
cycling	I-I
and	O
immersed	O
in	O
50	O
%	O
silver	B-I
nitrate	I-I
solutions	I-I
for	O
8	O
h	O
in	O
total	O
darkness	O
.	O


Each	O
slice	O
was	O
immersed	O
into	O
photo	O
developing	O
solution	O
and	O
was	O
photographed	O
,	O
and	O
microleakage	B-OUT
was	I-OUT
scored	I-OUT
from	I-OUT
0	I-OUT
to	I-OUT
7	I-OUT
,	O
by	O
three	O
calibrated	O
examiners	O
.	O


Dexmedetomidine	B-I
pretreatment	O
alleviates	O
propofol	B-P
injection	I-P
pain	I-P
.	I-P


OBJECTIVE	O
The	O
incidence	O
of	O
propofol	B-I
injection	O
pain	O
during	O
induction	O
of	O
general	O
anesthesia	O
varies	O
from	O
28	O
%	O
to	O
90	O
%	O
.	O


METHODS	O
Patients	B-P
undergoing	I-P
elective	I-P
surgical	I-P
procedures	I-P
were	I-P
randomly	I-P
allocated	I-P
into	I-P
seven	I-P
groups	I-P
of	I-P
30	I-P
patients	I-P
each	I-P
.	I-P


The	B-OUT
median	I-OUT
pain	I-OUT
score	I-OUT
and	I-OUT
number	I-OUT
of	I-OUT
patients	I-OUT
with	I-OUT
pain	I-OUT
scores	I-OUT
>	O
2	O
in	O
group	O
VII	O
were	O
both	O
significantly	O
less	O
than	O
in	O
the	O
control	O
(	O
group	O
I	O
;	O
p	O
=	O
0.000	O
,	O
both	O
)	O
.	O


CONCLUSIONS	O
Pretreatment	O
with	O
intravenous	B-I
DEX	O
1	O
µg/kg	O
5	O
min	O
prior	O
to	O
injection	O
of	O
long-chain	O
triglyceride	O
propofol	O
is	O
effective	O
and	O
safe	O
in	O
reducing	O
the	O
incidence	O
and	O
severity	O
of	O
pain	O
due	O
to	O
propofol	O
injection	O
.	O


METHODS	O
We	O
have	O
developed	O
a	O
low-tilt	B-I
biphasic	I-I
waveform	I-I
for	O
defibrillation	O
.	O


This	O
low-tilt	B-I
waveform	I-I
was	O
compared	O
with	O
a	O
conventional	B-I
waveform	I-I
of	O
equivalent	O
duration	O
and	O
voltage	O
in	O
patients	B-P
with	I-P
AF	I-P
.	I-P


Patients	B-P
with	I-P
persistent	I-P
AF	I-P
or	I-P
AF	I-P
induced	I-P
during	I-P
a	I-P
routine	I-P
electrophysiology	I-P
study	I-P
(	I-P
EPS	I-P
)	I-P
were	O
randomized	O
to	O
receive	O
either	O
the	O
low-tilt	B-I
waveform	I-I
or	O
a	O
conventional	B-I
waveform	I-I
.	I-I


Shock	O
success	O
was	O
defined	O
as	O
return	B-OUT
of	I-OUT
sinus	I-OUT
rhythm	I-OUT
for	O
>	O
/=30	O
seconds	O
.	O


METHODS	O
Of	O
57	B-P
patients	I-P
for	I-P
whom	I-P
we	I-P
thought	I-P
an	I-P
operative	I-P
intervention	I-P
was	I-P
necessary	I-P
,	O
30	O
cases	O
in	O
the	O
first	O
group	O
had	O
a	O
TURP	B-I
and	O
24	O
cases	O
in	O
the	O
second	O
group	O
had	O
a	O
PKRP	B-I
.	I-I


Operation	B-OUT
times	I-OUT
,	I-OUT
urethral	I-OUT
catheterization	I-OUT
times	I-OUT
,	I-OUT
preoperative	I-OUT
and	I-OUT
postoperative	I-OUT
Hb	I-OUT
,	I-OUT
Htc	I-OUT
and	I-OUT
serum	I-OUT
Na	I-OUT
values	I-OUT
of	O
the	O
patients	O
were	O
compared	O
and	O
the	O
complications	O
of	O
the	O
groups	O
were	O
also	O
compared	O
.	O


RESULTS	O
On	O
first	O
month	O
and	O
first	O
year	O
follow	O
up	O
between	O
the	O
groups	O
,	O
there	O
was	O
no	O
significant	O
statistical	B-OUT
difference	I-OUT
in	O
I-PSS	B-OUT
,	I-OUT
maximum	I-OUT
flow	I-OUT
rate	I-OUT
,	I-OUT
average	I-OUT
flow	I-OUT
,	I-OUT
residual	I-OUT
urine	I-OUT
and	I-OUT
size	I-OUT
of	I-OUT
the	I-OUT
prostate	I-OUT
.	I-OUT


The	O
decrease	O
in	O
serum	B-OUT
Na	I-OUT
level	I-OUT
was	O
found	O
to	O
be	O
significantly	O
higher	O
in	O
the	O
TURP	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O


The	O
operation	B-OUT
times	I-OUT
were	O
not	O
significantly	O
different	O
between	O
the	O
groups	O
.	O


CONCLUSION	O
It	O
is	O
obvious	O
that	O
PKRP	B-I
is	O
as	O
efficient	O
as	O
TURP	O
and	O
it	O
has	O
a	O
similar	O
morbidity	O
.	O


Differential	O
response	O
to	O
resistance	B-I
training	I-I
in	O
CHF	O
according	O
to	O
ACE	O
genotype	O
.	O


METHODS	O
The	O
relationship	O
between	O
ACE	O
genotype	O
and	O
the	O
response	O
to	O
11weeks	B-I
of	I-I
resistance	I-I
exercise	I-I
training	I-I
was	O
determined	O
in	O
37	B-P
CHF	I-P
patients	I-P
(	I-P
New	I-P
York	I-P
Heart	I-P
Association	I-P
Functional	I-P
Class=2.3±0.5	I-P
;	I-P
left	I-P
ventricular	I-P
ejection	I-P
fraction	I-P
28±7	I-P
%	I-P
;	I-P
age	I-P
64±12years	I-P
;	I-P
32:5	I-P
male	I-P
:	I-P
female	I-P
)	I-P
who	I-P
were	I-P
randomised	I-P
to	O
either	B-I
resistance	I-I
exercise	I-I
(	O
n=19	O
)	O
or	B-I
inactive	I-I
control	I-I
group	I-I
(	O
n=18	O
)	O
.	O


The	O
acute	O
effects	O
of	O
fluid	O
intake	O
on	O
urine	O
specific	O
gravity	O
and	O
fluid	O
retention	O
in	O
a	B-P
mildly	I-P
dehydrated	I-P
state	I-P
.	I-P


The	O
day-to-day	O
variability	O
in	O
morning	O
USG	O
(	O
coefficient	O
of	O
variation	O
=	O
0.2	O
±	O
0.1	O
%	O
)	O
was	O
low	O
and	O
the	O
responses	O
to	O
600	O
ml	O
of	O
W	O
ingestion	O
were	O
repeatable	B-OUT
.	I-OUT


Adjunctive	O
perampanel	B-I
for	O
refractory	O
partial-onset	O
seizures	O
:	O
randomized	O
phase	O
III	O
study	O
304	O
.	O


METHODS	O
This	O
was	O
a	O
multicenter	O
,	O
double-blind	O
,	O
placebo-controlled	O
trial	O
(	O
ClinicalTrials.gov	O
identifier	O
:	O
NCT00699972	O
)	O
.	B-P


Following	O
baseline	O
(	O
6	O
weeks	O
)	O
,	O
patients	O
entered	O
a	O
19-week	O
double-blind	O
phase	B-I
:	I-I
6-week	I-I
titration	I-I
(	I-I
2	I-I
mg/week	I-I
increments	I-I
to	I-I
target	I-I
dose	I-I
)	I-I
followed	I-I
by	I-I
a	I-I
13-week	I-I
maintenance	I-I
period	I-I
.	O


Using	O
this	O
intent-to-treat	O
population	O
over	O
the	O
double-blind	O
phase	O
,	O
the	B-OUT
median	I-OUT
percent	I-OUT
change	I-OUT
in	I-OUT
seizure	I-OUT
frequency	I-OUT
was	O
-21.0	O
%	O
,	O
-26.3	O
%	O
,	O
and	O
-34.5	O
%	O
for	B-I
placebo	I-I
and	I-I
perampanel	I-I
8	O
and	O
12	O
mg	O
,	O
respectively	O
(	O
p	O
=	O
0.0261	O
and	O
p	O
=	O
0.0158	O
for	O
8	O
and	O
12	O
mg	O
vs	O
placebo	O
,	O
respectively	O
)	O
.	O


Fifty	O
percent	O
responder	O
rates	O
during	O
the	O
maintenance	O
period	O
were	O
26.4	O
%	O
,	O
37.6	O
%	O
,	O
and	O
36.1	O
%	O
,	O
respectively	O
,	O
for	B-I
placebo	I-I
,	I-I
perampanel	I-I
8	O
mg	O
,	O
and	B-I
perampanel	I-I
12	O
mg	O
;	O
these	O
differences	O
were	O
not	O
statistically	O
significant	O
for	O
8	O
mg	O
(	O
p	O
=	O
0.0760	O
)	O
or	O
12	O
mg	O
(	O
p	O
=	O
0.0914	B-P
)	I-P
.	I-P


Sixty-eight	B-P
(	I-P
17.5	I-P
%	I-P
)	I-P
patients	I-P
discontinued	I-P
,	I-P
including	I-P
40	I-P
(	I-P
10.3	I-P
%	I-P
)	I-P
for	I-P
adverse	I-P
events	I-P
.	O


CLASSIFICATION	O
OF	O
EVIDENCE	O
This	O
study	O
provides	O
Class	O
I	O
evidence	O
that	O
once-daily	O
8	O
and	O
12	O
mg	O
doses	O
of	O
adjunctive	B-I
perampanel	I-I
are	O
effective	O
in	O
patients	O
with	O
uncontrolled	O
partial-onset	O
seizures	O
.	O
